CAMP4 Therapeutics Corporation beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -22.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.24 | $-0.22 | +8.3% | Beat | |
| Q1 FY26 | $-0.21 | $-0.32 | -52.4% | Miss | |
| Q4 FY25 | not reported | $-0.87 | not reported | not reported |
Back to CAMP overview · CAMP holders · CAMP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.